November 27, 2006Proceedings of the National Academy of SciencesOpen Access

Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness

View Full Paper

Ask AI

Bookmark

Population

Preclinical models: 8- and 10-week-old C57BL/6 female mice, 10-week-old athymic nude mice, and murine cell…

Comparison

In vivo ANGPTL4 gene transfer by electrotransfer… vs Control mice injected with pcDNA3.1-mycHis empty…

Design

Preclinical, randomized groups

Follow-up

up to 4 weeks

Authors

AGAriane GalaupCentre National de la Recherche Scientifique ACAurélie CazesUniversité Paris Cité SJSébastien Le JanUniversité de Reims Champagne-Ardenne

Discussion

Member takes

Implication

ANGPTL4 modulation warrants preclinical follow-up as an antimetastatic approach; human studies needed before any clinical consideration.

Structured PICO

Population

Preclinical models: 8- and 10-week-old C57BL/6 female mice, 10-week-old athymic nude mice, and murine cell lines (3LL Lewis lung carcinoma, B16F0 melanoma).

Intervention

In vivo ANGPTL4 gene transfer by electrotransfer (pcDNA3.1-ANGPTL4-mycHis plasmid) or recombinant ANGPTL4.

Comparator

Control mice injected with pcDNA3.1-mycHis empty plasmid or control buffer.

Outcome

Tumor metastasis (intravasation, extravasation, lung metastases) and vascular permeability.surrogate

In preclinical models, ANGPTL4 prevents tumor metastasis by inhibiting vascular permeability, tumor cell motility, and invasiveness.

Cite This Study

Galaup et al. (2006) studied this question.

synapsesocial.com/papers/6a7f8efefb3b41a99728bde9 https://doi.org/10.1073/pnas.0609025103

View Full Paper

Ask AI

Bookmark

November 27, 2006Proceedings of the National Academy of SciencesOpen Access

Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness

View Full Paper

Ask AI

Bookmark

Population

Preclinical models: 8- and 10-week-old C57BL/6 female mice, 10-week-old athymic nude mice, and murine cell…

Comparison

In vivo ANGPTL4 gene transfer by electrotransfer… vs Control mice injected with pcDNA3.1-mycHis empty…

Design

Preclinical, randomized groups

Follow-up

up to 4 weeks

Authors

AGAriane GalaupCentre National de la Recherche Scientifique ACAurélie CazesUniversité Paris Cité SJSébastien Le JanUniversité de Reims Champagne-Ardenne

Discussion

Member takes

Implication

ANGPTL4 modulation warrants preclinical follow-up as an antimetastatic approach; human studies needed before any clinical consideration.

Structured PICO

Population

Preclinical models: 8- and 10-week-old C57BL/6 female mice, 10-week-old athymic nude mice, and murine cell lines (3LL Lewis lung carcinoma, B16F0 melanoma).

Intervention

In vivo ANGPTL4 gene transfer by electrotransfer (pcDNA3.1-ANGPTL4-mycHis plasmid) or recombinant ANGPTL4.

Comparator

Control mice injected with pcDNA3.1-mycHis empty plasmid or control buffer.

Outcome

Tumor metastasis (intravasation, extravasation, lung metastases) and vascular permeability.surrogate

In preclinical models, ANGPTL4 prevents tumor metastasis by inhibiting vascular permeability, tumor cell motility, and invasiveness.

Cite This Study

Galaup et al. (2006) studied this question.

synapsesocial.com/papers/6a7f8efefb3b41a99728bde9 https://doi.org/10.1073/pnas.0609025103

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark